InvestorsHub Logo
Post# of 252186
Next 10
Followers 833
Posts 119839
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 250036

Wednesday, 12/13/2023 9:06:30 AM

Wednesday, December 13, 2023 9:06:30 AM

Post# of 252186
PFE provides 2024 guidance including SGEN:

https://s28.q4cdn.com/781576035/files/doc_downloads/2023/12/Pfizer-Provides-Full-Year-2024-Guidance-FINAL-12-13-23.pdf

▪ Full-Year 2024 Revenue Guidance Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition

- Anticipates Approximately $8 Billion in Revenues for Comirnaty and Paxlovid

- Seagen Expected to Contribute Approximately $3.1 Billion of Revenues

▪ Expects Full-Year 2024 Operational [i.e. constant currency] Revenue Growth of 8%-10% Including Seagen Contribution and Excluding Comirnaty and Paxlovid Revenues, and 3%-5% Excluding Both Seagen Contribution and Comirnaty and Paxlovid Revenues

▪ 2024 Adjusted Diluted [i.e. non-GAAP] EPS Guidance Range of $2.05 to $2.25 Includes Expected Impact of Seagen Acquisition

▪ Enterprise-Wide Cost Realignment Program Now Expected to Deliver Annual Net Cost Savings of at Least $4.0 Billion, an Incremental $500 Million Versus Mid-Point of Guidance Range Provided on August 1, 2023

CC slides:
https://s28.q4cdn.com/781576035/files/doc_downloads/2023/12/2024-Financial-Guidance-Presentation_Dec-13-2023_vF.pdf

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.